Picture of Celltrion Healthcare Co logo

091990 — Celltrion Healthcare Co News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

Brief: Celltrion’S Monoclonal Antibody Treatment Regdanvimab, Approved By European Commission For Treatment Of Covid-19

Nov 14 (Reuters) - Celltrion HealthCare Co Ltd  091990.KQ :
    * CELLTRION’S MONOCLONAL ANTIBODY TREATMENT REGDANVIMAB,
APPROVED
BY THE EUROPEAN COMMISSION FOR THE TREATMENT OF COVID-19
    * CELLTRION HEALTHCARE -  EC GRANTED MARKETING AUTHORISATION
FOR
CO'S REGDANVIMAB AFTER POSITIVE OPINION BY EMA'S CHMP LAST WEEK
    * CELLTRION - EC GRANTED MARKETING AUTHORISATION FOR ADULTS
WITH
COVID-19 WHO DO NOT REQUIRE SUPPLEMENTAL OXYGEN & ARE AT RISK OF
SEVERE COVID-19
    * CELLTRION HEALTHCARE -CONTINUES TO DISCUSS SUPPLY
AGREEMENTS
WITH REGULATORY AGENCIES, CONTRACTORS IN MORE THAN 30 COUNTRIES
IN EUROPE, ASIA, LATAM

Source text for Eikon:  ID:nBw9PTYYJa 
Further company coverage:  091990.KQ 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Celltrion Healthcare Co

See all news